InspireMD (STU:II2) Net Income From Continuing Operations: €-44.55 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:II2 InspireMD Inc STU:II2
47 GF Score
Price €0.65
GF Value €1.31
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is InspireMD Net Income From Continuing Operations?

InspireMD STU:II2 +3.13% 47 Net Income From Continuing Operations is €-44.55 Mil as of Jun. 2026. GuruFocus rates STU:II2 with a GF Score™ of 47/100 and a GF Value™ of €1.31 (Possible Value Trap). The stock has 3 warning signs investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. InspireMD's net income from continuing operations for the three months ended in Jun. 2026 was €-12.39 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-44.55 Mil.

InspireMD Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for InspireMD's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InspireMD Net Income From Continuing Operations Chart

InspireMD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.62 -17.59 -18.42 -29.59 -43.23

InspireMD Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.84 -10.23 -10.23 -11.70 -12.39
STU:II2
47GF Score
InspireMD Inc STU:II2
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InspireMD Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-44.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of €-44.55 Mil mean?
InspireMD (STU:II2) has a Net Income From Continuing Operations of €-44.55 Mil as of Jun. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for InspireMD and its competitors.
Is InspireMD's Net Income From Continuing Operations too high?
InspireMD's current Net Income From Continuing Operations is €-44.55 Mil. Overall, InspireMD has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's Net Income From Continuing Operations compare to SNWV and PAVM?
InspireMD's Net Income From Continuing Operations of €-44.55 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Medical Devices & Instruments company?
A good Net Income From Continuing Operations depends on the Medical Devices & Instruments industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for InspireMD and its competitors. InspireMD's current Net Income From Continuing Operations is €-44.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.31, compared to a current price of €0.65 — trading 50.4% below its estimated fair value. The current Net Income From Continuing Operations is €-44.55 Mil. InspireMD's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For InspireMD (STU:II2), the current Net Income From Continuing Operations is €-44.55 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InspireMD (STU:II2) Overvalued in 2026?

Based on GuruFocus' analysis, InspireMD stock appears to be undervalued. The current stock price of €0.65 is trading 50.4% below its estimated GF Value™ of €1.31. GuruFocus considers InspireMD to be Possible Value Trap.

Key valuation signals for STU:II2:

  • Net Income From Continuing Operations: €-44.55 Mil
  • GF Value™: €1.31 vs. price of €0.65 (50.4% below fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InspireMD Business Description

Other Exchanges NSPR:USA
Address 6303 Waterford District Drive, Suite 215, Miami, FL, USA, 33126
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
47GF Score

Get the complete analysis for STU:II2

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.65
Price
€1.31
GF Value